These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 3444799)

  • 21. Determinants of serum T4 and T3 at the time of diagnosis in nosological types of thyrotoxicosis: a population-based study.
    Carlé A; Knudsen N; Pedersen IB; Perrild H; Ovesen L; Rasmussen LB; Laurberg P
    Eur J Endocrinol; 2013 Nov; 169(5):537-45. PubMed ID: 23935127
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Thyroid stimulating immunoglobulin bioactivity during carbimazole therapy as measured by the cytochemical bioassay.
    Prentice MG; Rayman GA; Alaghband-Zadeh J; Wise PH
    J Endocrinol Invest; 1987 Oct; 10(5):483-9. PubMed ID: 2892877
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunoglobulins of untreated Graves' patients with or without thyrotropin receptor antibody (determined by porcine thyrocytes) universally elicit potent thyroid hormone-releasing activity in cultured human thyroid follicles.
    Sato K; Yamazaki K; Yamada E; Kanaji Y; Miura M; Obara T
    Thyroid; 1999 Oct; 9(10):979-88. PubMed ID: 10560951
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Thyroid function parameters and TSH-receptor antibodies in healthy subjects and Graves' disease patients: a sequential study before, during and after pregnancy.
    González-Jiménez A; Fernández-Soto ML; Escobar-Jiménez F; Glinoer D; Navarrete L
    Thyroidology; 1993 Apr; 5(1):13-20. PubMed ID: 7508738
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differential evolution of thyroid peroxidase and thyrotropin receptor antibodies in Graves' disease: thyroid peroxidase antibody activity reverts to pretreatment level after carbimazole withdrawal.
    Guilhem I; Massart C; Poirier JY; Maugendre D
    Thyroid; 2006 Oct; 16(10):1041-5. PubMed ID: 17042691
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Serum thyroid hormones and TSH response to TRH during treatment of Graves' disease by carbimazole (author's transl)].
    Lorcy Y; Heim J; Auvray E; Allannic H
    Ann Endocrinol (Paris); 1979; 40(4):441-2. PubMed ID: 117739
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Medical therapy of Graves' disease: does thyroxine prevent recurrence of hyperthyroidism?
    Lucas A; Salinas I; Rius F; Pizarro E; Granada ML; Foz M; Sanmartí A
    J Clin Endocrinol Metab; 1997 Aug; 82(8):2410-3. PubMed ID: 9253309
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Hyperthyroidism in a premature infant due to transplacental passage of maternal thyrotropin receptor antibodies].
    Rink T; Wieg C; Schroth HJ; Helisch A; Bertram U
    Nuklearmedizin; 1999; 38(5):156-9. PubMed ID: 10488483
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prediction of remission or relapse for Graves' hyperthyroidism by the combined determination of stimulating, blocking and binding TSH-receptor antibodies after the withdrawal of antithyroid drug treatment.
    Wallaschofski H; Miehle K; Mayer A; Tuschy U; Hentschel B; Paschke R
    Horm Metab Res; 2002 Jul; 34(7):383-8. PubMed ID: 12189586
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Analysis of circulating thyroid-stimulating activities in pregnant women with Graves' disease: differential measurement of activities induced by TSH receptor antibody and hCG].
    Kaneda T; Tamaki H; Hidaka Y; Amino N; Mitsuda N; Tanizawa O; Miyai K
    Rinsho Byori; 1992 Sep; 40(9):941-7. PubMed ID: 1434029
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Graves' ophthalmopathy in the absence of elevated free thyroxine and triiodothyronine levels: prevalence, natural history, and thyrotropin receptor antibody levels.
    Khoo DH; Eng PH; Ho SC; Tai ES; Morgenthaler NG; Seah LL; Fong KS; Chee SP; Choo CT; Aw SE
    Thyroid; 2000 Dec; 10(12):1093-100. PubMed ID: 11201855
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Administration of thyroxine in treated Graves' disease. Effects on the level of antibodies to thyroid-stimulating hormone receptors and on the risk of recurrence of hyperthyroidism.
    Hashizume K; Ichikawa K; Sakurai A; Suzuki S; Takeda T; Kobayashi M; Miyamoto T; Arai M; Nagasawa T
    N Engl J Med; 1991 Apr; 324(14):947-53. PubMed ID: 1900575
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Binding, stimulating and blocking TSH receptor antibodies to the thyrotropin receptor as predictors of relapse of Graves' disease after withdrawal of antithyroid treatment.
    Quadbeck B; Hoermann R; Hahn S; Roggenbuck U; Mann K; Janssen OE
    Horm Metab Res; 2005 Dec; 37(12):745-50. PubMed ID: 16372228
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interaction of thyroid-stimulating antibody with Graves' thyroid-stimulating hormone-binding antibody.
    Ochi Y; Kajita Y; Hamazu M; Nagata A
    Horm Res; 2003; 59(5):222-8. PubMed ID: 12714785
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Thyrotoxicosis--treatment by I131 therapy and early prediction of hypothyroidism following this therapy.
    Khanna CM; Jain SK; Walia RP
    J Assoc Physicians India; 1994 Jan; 42(1):36-8. PubMed ID: 7836246
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of TSH measurements in predicting the outcome of treatment for Graves' disease following drug therapy.
    Wood WE
    Postgrad Med J; 1995 Apr; 71(834):222-3. PubMed ID: 7784282
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serum thyrotropin receptor antibodies concentrations in patients with Graves' disease before, at the end of methimazole treatment, and after drug withdrawal: evidence that the activity of thyrotropin receptor antibody and/or thyroid response modify during the observation period.
    Carella C; Mazziotti G; Sorvillo F; Piscopo M; Cioffi M; Pilla P; Nersita R; Iorio S; Amato G; Braverman LE; Roti E
    Thyroid; 2006 Mar; 16(3):295-302. PubMed ID: 16571093
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Thyrotrophin displacement activity of serum immunoglobulins in health and disease.
    Croxson MS; Lim TM; Graham FM; Ibbertson HK
    Aust N Z J Med; 1980 Apr; 10(2):151-6. PubMed ID: 6930204
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Thyroid stimulating hormone receptor antibody in thyroid diseases.
    Vadivelu N; Stephen DC; Kanagasabapathy AS; Seshadri MS
    Indian J Med Res; 1990 Aug; 92():220-3. PubMed ID: 1977696
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Remission of Graves' hyperthyroidism predicted by smooth decreases of thyroid-stimulating antibody and thyrotropin-binding inhibitor immunoglobulin during antithyroid drug treatment.
    Takasu N; Yamashiro K; Komiya I; Ochi Y; Sato Y; Nagata A
    Thyroid; 2000 Oct; 10(10):891-6. PubMed ID: 11081255
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.